Skip to main content
logo
QuidelOrtho Corporation (QDEL)
NASDAQ: QDEL · Real-Time Price · USD
11.41
+0.17 (1.51%)
Apr 24, 2026, 1:26 PM EDT - Market open

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Dec '25 Dec '24 Dec '23 Jan '23 Jan '22 Jan '21 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14
North America Revenue
1.49B1.62B
North America Revenue Growth
-8.08%-13.71%
EMEA Revenue
360.70M335.80M
EMEA Revenue Growth
7.41%2.60%
China Revenue
334.70M325.00M
China Revenue Growth
2.99%4.81%
JPAC Revenue
293.00M279.40M
JPAC Revenue Growth
4.87%-
Latin America Revenue
252.90M222.90M
Latin America Revenue Growth
13.46%-
Other Geographies Revenue
545.90M502.30M
Other Geographies Revenue Growth
8.68%3.93%
Revenue (Total)
2.73B2.78B
Revenue (Total) Growth
-1.89%-7.17%

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Dec '25 Dec '24 Dec '23 Jan '23 Jan '22 Jan '21 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14
Labs Revenue
1.51B1.43B
Labs Revenue Growth
5.50%0.13%
Immunohematology Revenue
543.80M522.00M
Immunohematology Revenue Growth
4.18%1.87%
Donor Screening Revenue
52.60M115.10M
Donor Screening Revenue Growth
-54.30%-15.43%
Transfusion Medicine Revenue
596.40M637.10M
Transfusion Medicine Revenue Growth
-6.39%-1.76%
Point of Care Revenue
601.60M694.60M
Point of Care Revenue Growth
-13.39%-22.15%
Molecular Diagnostics Revenue
26.50M24.00M
Molecular Diagnostics Revenue Growth
10.42%-24.29%
Revenue (Total)
2.73B2.78B
Revenue (Total) Growth
-1.89%-7.17%

Adjusted EBITDA by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Dec '25 Dec '24 Dec '23 Jan '23 Jan '22 Jan '21 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14
North America Adjusted EBITDA
807.00M892.10M
North America Adjusted EBITDA Growth
-9.54%-12.98%
EMEA Adjusted EBITDA
82.60M46.50M
EMEA Adjusted EBITDA Growth
77.63%13.41%
China Adjusted EBITDA
141.20M130.50M
China Adjusted EBITDA Growth
8.20%2.59%
JPAC Adjusted EBITDA
73.20M69.90M
JPAC Adjusted EBITDA Growth
4.72%19.49%
Latin America Adjusted EBITDA
78.40M63.60M
Latin America Adjusted EBITDA Growth
23.27%11.97%
Other Geographies Adjusted EBITDA
151.60M133.50M
Other Geographies Adjusted EBITDA Growth
13.56%15.78%
Corporate Adjusted EBITDA
-585.40M-659.70M
Operating Income (Total)
-919.20M-1.96B
Updated Dec 28, 2025. Data Source: Fiscal.ai.